trapezoid glp-1 glp 1 use tripled among non-diabetics, reaching $5.8B in 2022 dose GLP Randomised trial comparing weight loss

These users report appreciating treatment benefits while active but watching improvements gradually fade over months post-discontinuation, with timeline showing first 2 months maintaining most benefits creating initial optimism, months 2-4 showing noticeable decline returning toward baseline, months 4-8 continuing regression approaching pre-treatment status, and stabilization occurring 60-80% back toward original baseline with only modest long-term improvement retention

BYETTA (exenatide) injection

Zhao R, Zhou H, Su SB

Muscle supports metabolism, strength, and long-term weight maintenance

For more on which water to use for peptide reconstitution , our dedicated guide explains every option